EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"5965741"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:08
S2	1267	514/471.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:08
S3	5	S2 and opiod	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:08
S4	52	S2 and opioid	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:09
S5	0	phenoxymenthyl adj benzamide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:10
S6	21	phenoxymethyl adj benzamide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:10
S7	2	"5965741"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:56

EAST Search History

S8	10	"026305"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:56
S9	189	"26305"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 09:57
S10	8	"7001914"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 11:06
S11	140	"42271"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/11/19 11:06

10598696

L10 0 SEA SSS SAM L9

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839 AND 2005 AND 1993

L11 SCREEN CREATED

=> screen 1841 OR 1929 OR 2021 OR 2026 OR 2016 OR 2007 OR 1994

L12 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10598696screen.str



chain nodes :
7 8 9 10 12 19 21 22 25 27 29
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
11 13 20
chain bonds :
5-7 7-8 8-9 9-27 10-19 10-29 11-12 12-13 20-21 21-22 27-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6

10598696

exact/norm bonds :
7-8 8-9 10-19 10-29 11-12 12-13 20-21 21-22
exact bonds :
5-7 9-27 27-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 25:CLASS
26:Atom 27:Atom
29:CLASS
Generic attributes :
27:
Saturation   : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

Element Count :
Node 27: Limited
    C,C6

L13   STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12

=> s l14
SAMPLE SEARCH INITIATED 17:58:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   8119 TO ITERATE

 24.6% PROCESSED   2000 ITERATIONS   1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 156979 TO   167781
PROJECTED ANSWERS: 1 TO   201

L15   1 SEA SSS SAM L13 AND L11 NOT L12

=> s l14 full
FULL SEARCH INITIATED 17:58:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   161501 TO ITERATE

100.0% PROCESSED   161501 ITERATIONS   12 ANSWERS
SEARCH TIME: 00.00.02

L16   12 SEA SSS FUL L13 AND L11 NOT L12

=> d scan

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[3-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]-
MF C20 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2000

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[[methyl(3-methylbutyl)amino]methyl]phenoxy]methyl]-
MF C21 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]methyl]-
MF C21 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]methyl]-
MF C22 H28 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[2-[(phenylmethyl)amino]ethyl]phenoxy]methyl]-
MF C23 H24 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[4-[(2S)-2-(methyl-2-propyn-1-ylamino)-3-buten-1-yl]phenoxy]methyl]-
MF C22 H24 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[(2S)-2-(methyl-2-propyn-1-ylamino)-3-buten-1-yl]phenoxy]methyl]-
MF C22 H24 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C22 H20 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]-
MF C20 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]-
MF C20 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[2-[4-[[(3-methylbutyl)amino]methyl]phenoxy]ethyl]-
MF C21 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 12 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 2-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]-
MF C20 H26 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 17:44:15 ON 16 NOV 2007)

FILE 'REGISTRY' ENTERED AT 17:44:24 ON 16 NOV 2007
L1 STRUCTURE UPLOADED
L2 0 S L1

FILE 'STNGUIDE' ENTERED AT 17:44:58 ON 16 NOV 2007

FILE 'REGISTRY' ENTERED AT 17:46:02 ON 16 NOV 2007
L3 STRUCTURE UPLOADED
L4 1 S L3
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 STRUCTURE UPLOADED
L8 0 S L7
L9 STRUCTURE UPLOADED
L10 0 S L9
L11 SCREEN 1839 AND 2005 AND 1993
L12 SCREEN 1841 OR 1929 OR 2021 OR 2026 OR 2016 OR 2007 OR 19
L13 STRUCTURE UPLOADED
L14 QUE L13 AND L11 NOT L12
L15 1 S L14
L16 12 S L14 FULL

=> file caplus
FILE 'CAPLUS' ENTERED AT 17:58:38 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 15 Nov 2007 (20071115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l16
L17 2 L16

=> d cbib abs hitstr 1-2

L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2007:17777 Document No. 146:115047 MAO-B inhibitors useful for treating obesity. McElroy, John Francis; Chorvat, Robert J.; Parthasarathi, Rajagopalan (Jenrin Discovery, USA). U.S. Pat. Appl. Publ. US 2007004683 A1 20070104, 71pp. (English). CODEN: USXXCO. APPLICATION: US 2006-427846 20060630. PRIORITY: US 2005-696067P 20050701.

AB The invention provides novel compds. that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

IT 918109-56-5P 918109-57-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MAO-B inhibitors useful for treating obesity)

RN 918109-56-5 CAPLUS
CN Benzamide, 4-[[4-[(2S)-2-(methyl-2-propyn-1-ylamino)-3-buten-1-yl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 918109-57-6 CAPLUS
CN Benzamide, 3-[[4-[(2S)-2-(methyl-2-propyn-1-ylamino)-3-buten-1-yl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2005:1042204 Document No. 143:346926 Preparation of benzamide derivatives as opioid receptor antagonists. De la Torre, Marta Garcia; Mitch, Charles Howard (Eli Lilly and Company, USA). PCT Int. Appl. WO 2005090286 A1 20050929, 41 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US7051 20050308. PRIORITY: EP 2004-380058 20040312; US 2004-553184P 20040315.

GI



I



II

AB Title compds. represented by the formula I [wherein X1, X2 = independently CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; R6, R7 = independently H, alkyl(aryl), alkenyl, etc.; m, m' = independently 0-2; n, n' = independently 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 3-(hydroxymethyl)benzonitrile with 4-hydroxybenzaldehyde. I were tested for antagonistic activity of mu-, γ- and δ-opioid receptor in SPA-based GTPγS binding

assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical compns. are useful as opioid receptor antagonists for the treatment of obesity (no data).

IT 865539-91-9P 865539-93-1P 865539-96-4P
865539-97-5P, 2-[[4-[(3-Methylbutylamino)methyl]phenoxy]methyl]benzamide 865539-98-6P, 3-[[3-[(3-Methylbutylamino)methyl]phenoxy]methyl]benzamide 865539-99-7P, 3-[[4-[[Methyl(3-methylbutyl)amino]methyl]phenoxy]methyl]benzamide 865540-00-7P, 3-[[4-[(3,3-Dimethylbutylamino)methyl]phenoxy]methyl]benzamide 865540-01-8P, 3-[[4-[[[2-(Tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]methyl]benzamide 865540-07-4P, 3-[[4-(2-Benzylaminoethyl)phenoxy]methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. as opioid receptor antagonists)

RN 865539-91-9 CAPLUS
CN Benzamide, 3-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865539-93-1 CAPLUS
CN Benzamide, 4-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865539-96-4 CAPLUS
CN Benzamide, 4-[2-[4-[[(3-methylbutyl)amino]methyl]phenoxy]ethyl]- (CA INDEX NAME)



RN 865539-97-5 CAPLUS
CN Benzamide, 2-[[4-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865539-98-6 CAPLUS
CN Benzamide, 3-[[3-[[(3-methylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865539-99-7 CAPLUS
CN Benzamide, 3-[[4-[[methyl(3-methylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865540-00-7 CAPLUS
CN Benzamide, 3-[[4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865540-01-8 CAPLUS
CN Benzamide, 3-[[4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 865540-07-4 CAPLUS
CN Benzamide, 3-[[4-[2-[(phenylmethyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)



=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 18:05:53 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).



3-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide



4- {4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



4-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,



4- {4-[(3 -Methyl-butylamino)-methyl]-benzyloxy } -benzamide,



4-(2- {4-[(3 -Methyl-butylamino)-methyl]-phenoxy } -ethyl)-benzamide,



2- {4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



3-{3-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



3-(4-{(Methyl-(3-methyl-butyl)-amino)-methyl}-phenoxymethyl)-benzamide,



3-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



3-(4- {[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxymethyl)-benzamide,



3-(4- {[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxymethyl)-benzamide,



3-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,



3 - {4-[(3 -Methyl-butylamino)-methyl]-benzyloxy } -benzamide,



4- {3-[2-(3-Methyl-butylamino)-ethyl]-benzyloxy}-benzamide,



3-[4-(2-Benzylamino-ethyl)-Phenoxymethyl]-benzamide,



3-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



4-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,



4-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,



4- {4-[(3 -Methyl-butylamino)-methyl]-benzyloxy } -benzamide,



4-(2- {4-[(3-Methyl-butylamino)-methyl]-phenoxy}-ethyl)-benzamide